Objective: to offer Quebec's 3,000 researchers in human health the
possibility of submitting innovative projects
MONTREAL, March 17 /CNW Telbec/ - Pfizer Canada and the Fonds de la
recherche en santé du Québec (FRSQ) today announced an unprecedented
partnership for the creation of the Pfizer-FRSQ Innovation Fund. This fund
aims to stimulate public-sector research in human health in Quebec and to act
as a catalyst for the commercialization of innovative research projects.
Pfizer Canada will invest $10 million over a five-year period. The Fund,
managed by the FRSQ, will allow some 3,000 Quebec-based researchers in human
health to submit research projects that match the needs of the population in
Quebec and that offer a high potential for technology transfer and
commercialization over the short and medium terms.
The announcement was made today at the Université de Montréal's Institut
de recherche en immunologie et de cancérologie to representatives of Quebec's
public-sector research community, in the company of Mr. Raymond Bachand,
Quebec's Minister of Economic Development, Innovation and Export Trade and
Minister of Tourism.
Partnership and entrepreneurship
The goal of the Pfizer-FRSQ Fund is to support and reinforce the
potentially promising commercialization of public-sector research in human
health in Quebec in areas that are critical to public health. These include
AIDS and infectious diseases, mental illness, cancer, and inflammatory,
cardiovascular, metabolic and chronic diseases.
Members of Quebec's community of 3,000 experienced researchers will be
able to submit projects that must not only address major problems in human
health, but also be large-scale, involving several institutions. The projects
must also aim for concrete results that could lead to commercialization
efforts within three to five years as new therapeutic molecules, new knowledge
or new technological devices.
"Through its objectives and its approach, the Pfizer-FRSQ Innovation Fund
is an excellent example of the type of achievement sought by the Quebec
Strategy for Research and Innovation," said Mr. Raymond Bachand.
Mr. Paul Lévesque, president and CEO of Pfizer Canada, stated that
"Pfizer Canada is proud to contribute to the acceleration of Quebec's
knowledge-based economy in an advanced sector such as medical and
pharmaceutical research. Pfizer is creating this fund in collaboration with
the FRSQ because it believes in the potential for R&D in Quebec and that it is
crucial to develop better links between university research, patient needs,
and society's needs at large." He congratulated the government "for having put
into place an environment conducive to research and innovation by harmonizing
its policies in healthcare and the economy."
"We believe that the Pfizer-FRSQ Innovation Fund will allow Quebec to
strengthen its leadership position in R&D in human health in Canada," he
"By creating this fund with Pfizer Canada's contribution, the FRSQ aims
to stimulate the business spirit of Quebec's universities and hospital centres
and to encourage researchers to promote their discoveries in order to
accelerate their commercialization and their availability to patients,"
concluded Dr. Alain Beaudet, CEO of the FRSQ.
Each year, the FRSQ provides over $90 million in awards and grants for
public-sector research in human health conducted in universities and the
healthcare network's research centres. The creation of the Pfizer-FRSQ
Innovation Fund will provide Quebec's researchers into human health a unique
source of financing for large-scale research projects involving multiple
disciplines and institutions.
About the Fonds de la recherche en santé du Québec (FRSQ)
Reporting to the Minister of Economic Development, Innovation and Export
Trade and Minister of Tourism, the mission of the Fonds de la recherche en
santé du Québec (FRSQ) is to support health research in order to benefit the
Quebec population's well-being. Its mandate is to provide financial aid and to
promote this research, to share knowledge and to train researchers, as well as
to establish partnerships that are necessary to the development of Quebec's
research and innovation system and the advancement of research
internationally. For more information, visit www.frsq.gouv.qc.ca.
About Pfizer Canada Inc.
Pfizer Canada is the Canadian operation of Pfizer Inc., the world's
leading pharmaceutical company. Pfizer discovers, develops, manufactures and
markets prescription medicines for humans and animals. Pfizer Inc. invests
more than US$7 billion annually in R&D to discover and develop innovative
life-saving and life-enhancing medicines in a wide range of therapeutic areas,
including arthritis, cardiovascular disease, endocrinology, HIV/AIDS,
infectious disease, neurological disease, oncology, ophthalmology and smoking
cessation. Pfizer Canada is one of the top investors in Canadian R&D,
investing more than $130 million in 2006. Canadian headquarters of Pfizer
Global Pharmaceuticals is in Kirkland, Quebec. For more information, visit
Media access: ftp://ftp.national.ca/medias/PFIZER/17032008/
User code: presse
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
the CNW Photo Network and archived at http://photos.newswire.ca.
Additional archived images are also available on the CNW Photo Archive
website at http://photos.newswire.ca. Images are free to accredited
members of the media/
For further information:
For further information: Nadia Paquet, NATIONAL Public Relations, (514)
843-2351, Cellular: (514) 713-1350; Sylvie Tessier, Pfizer Canada, (514)
693-4609; Michelle Dubuc, FRSQ, (514) 873-2114 x 235